Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. •• AASLD I. AASLD IDSA hepatitis C guidelines. 2017(July 22) (2017). This website is an up to date set of guidelines published jointly by the AASLD and the IDSA. It is an excellent source of current information about the treatment of HCV.
2. Aggarwal A, Yoo ER, Perumpail RB, et al. Sofosbuvir use in the setting of end-stage renal disease: a single center experience. J Clin Transl Hepatol. 2017;5(1):23–6.
3. Alanio C, Nicoli F, Sultanik P et al. Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients. Elife. 4,
https://doi.org/10.7554/eLife.07916
. 2015.
4. Barsoum RS, William EA, Khalil SS. Hepatitis C and kidney disease: a narrative review. J Adv Res. 2017;8(2):113–30.
5. •• Bruchfeld A, Roth D, Martin P, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2017;2(8):585–94. This reports a large clinical trial of elbasvir and graszoprevir in 224 patients with stage 4-5 kidney disease